ResMed (NYSE: RMD) director sells 2,000 shares under 10b5-1 plan
Rhea-AI Filing Summary
ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | ResMed Common Stock | 2,000 | $251.47 | $503K |
Footnotes (1)
- F1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did ResMed (RMD) report in this Form 4?
A ResMed Inc. director reported selling 2,000 shares of ResMed common stock on 12/03/2025, as disclosed in the Form 4.
Was the ResMed (RMD) insider sale made under a Rule 10b5-1 trading plan?
Yes. The explanation of responses states the transaction was conducted under a Rule 10b5-1 plan adopted on August 12, 2025.
What is the reporting person’s relationship to ResMed (RMD)?
The reporting person is identified as a Director of ResMed Inc., and the signature block shows /s/ Peter C. Farrell, Chairman emeritus.
Is this ResMed (RMD) Form 4 filed by more than one reporting person?
No. The form indicates it is filed by one reporting person, not by more than one reporting person.